ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
I MAB

I MAB (IMAB)

1.43
-0.05
(-3.38%)
Closed July 20 4:00PM
1.43
0.00
(0.00%)
After Hours: 6:38PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.43
Bid
1.37
Ask
1.47
Volume
241,493
1.37 Day's Range 1.5588
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.48
Open
1.47
Last Trade
1
@
1.43
Last Trade Time
Financial Volume
$ 343,872
VWAP
1.4239
Average Volume (3m)
-
Shares Outstanding
80,701,592
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About I MAB

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Grand Cayman, Cym
Founded
1970
I MAB is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMAB. The last closing price for I MAB was $1.48. Over the last year, I MAB shares have traded in a share price range of $ 0.00 to $ 0.00.

I MAB currently has 80,701,592 shares outstanding. The market capitalization of I MAB is $119.44 million.

IMAB Latest News

I-Mab Announces Leadership Transitions

I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md., July 15, 2024 ROCKVILLE, Md., July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based...

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md., June 6, 2024 ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire ROCKVILLE, Md., June 5, 2024...

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
262.73M
AUGXAugmedix Inc
$ 2.27
(147.71%)
21.87M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.76M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.13k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
119.98M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.37M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
204.34k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.12M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
26.52M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

IMAB Discussion

View Posts
Monksdream Monksdream 2 weeks ago
IMAB under $2
👍️0
stock1ace1 stock1ace1 3 months ago
Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)
👍️0
Monksdream Monksdream 4 months ago
IMAB 10Q due 4/3
👍️0
Monksdream Monksdream 4 months ago
IMAB under $2=
👍️0
Monksdream Monksdream 4 months ago
IMAB under $2
👍️0
Monksdream Monksdream 5 months ago
IMAB under $2
👍️0
AGORDON AGORDON 5 months ago
IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?
👍️0
AGORDON AGORDON 7 months ago
2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.
👍️0
AGORDON AGORDON 7 months ago
Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.
👍️0
AGORDON AGORDON 7 months ago
Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.
👍️0
AGORDON AGORDON 7 months ago
From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.
👍️0
AGORDON AGORDON 7 months ago
In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.
👍️0
AGORDON AGORDON 8 months ago
The stock has bounced off $1.80 two times within a month.
👍️0
AGORDON AGORDON 8 months ago
Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.
👍️0
Mt. Blanc Mt. Blanc 8 months ago
IMAB climbing the charts tracking the $3s. Check it out soon.

mb
👍️0
Monksdream Monksdream 10 months ago
IMAB under $2
👍️0

Your Recent History

Delayed Upgrade Clock